Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H19ClF4N2O4 |
Molecular Weight | 486.844 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(Cl)C=CC=C1C2=CC(F)=C(C=C2)[C@@H](C)NC(=O)C3(CC3)NC(=O)C(F)(F)F
InChI
InChIKey=WZZIQHIQMWJNLU-LLVKDONJSA-N
InChI=1S/C22H19ClF4N2O4/c1-11(28-19(31)21(8-9-21)29-20(32)22(25,26)27)13-7-6-12(10-16(13)24)14-4-3-5-15(23)17(14)18(30)33-2/h3-7,10-11H,8-9H2,1-2H3,(H,28,31)(H,29,32)/t11-/m1/s1
Molecular Formula | C22H19ClF4N2O4 |
Molecular Weight | 486.844 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
MK-0686 is a bradykinin B1 receptor antagonist patented by American multinational pharmaceutical company Merck & Co for the treatment of neuropathic pain and inflammation. MK-0686 demonstrates significantly reduced susceptibility to human P-gp mediated efflux and shows good potential for human CNS penetration based on brain levels in CF-1 mice and monkeys. Additionally, MK-0686 also exhibited good CNS bradykinin B1 receptor occupancy in the transgenic rat expressing the human B1 receptor and showed oral efficacy in reducing CFA-induced hyperalgesia in a humanized mouse. Unfortunately, in phase II clinical trials MK-0686 failed to demonstrate efficacy in phase II clinical trials.
CNS Activity
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18310472
Rhesus monkey: 30 mg/kg/day, 60 mg/kg/day, and 150 mg/kg/day
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:28:07 GMT 2023
by
admin
on
Fri Dec 15 16:28:07 GMT 2023
|
Record UNII |
M310323W0U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
M310323W0U
Created by
admin on Fri Dec 15 16:28:07 GMT 2023 , Edited by admin on Fri Dec 15 16:28:07 GMT 2023
|
PRIMARY | |||
|
578727-68-1
Created by
admin on Fri Dec 15 16:28:07 GMT 2023 , Edited by admin on Fri Dec 15 16:28:07 GMT 2023
|
PRIMARY | |||
|
DB12563
Created by
admin on Fri Dec 15 16:28:07 GMT 2023 , Edited by admin on Fri Dec 15 16:28:07 GMT 2023
|
PRIMARY | |||
|
100000174919
Created by
admin on Fri Dec 15 16:28:07 GMT 2023 , Edited by admin on Fri Dec 15 16:28:07 GMT 2023
|
PRIMARY | |||
|
DTXSID20206587
Created by
admin on Fri Dec 15 16:28:07 GMT 2023 , Edited by admin on Fri Dec 15 16:28:07 GMT 2023
|
PRIMARY | |||
|
16102897
Created by
admin on Fri Dec 15 16:28:07 GMT 2023 , Edited by admin on Fri Dec 15 16:28:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL232943
Created by
admin on Fri Dec 15 16:28:07 GMT 2023 , Edited by admin on Fri Dec 15 16:28:07 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Ki
|
||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |